Hypertension Management

Introduction to Antihypertensive Medications

The American Heart Association recommends avoiding abrupt cessation of beta-blockers like nebivolol as this can lead to rebound hypertension 1
The European Society of Cardiology recommends nebivolol as an antihypertensive medication with unique properties compared to traditional beta-blockers, including less or no dysmetabolic action 2

Nebivolol demonstrates a reduced incidence of new-onset diabetes compared to classical beta-blockers, according to the European Society of Hypertension guidelines 3
Nebivolol is effective in lowering blood pressure, with its antihypertensive effect seen within two weeks of treatment and maintained over the 24-hour dosing interval, due to its highly selective beta-1 blocker properties and additional vasodilating effects related to nitric oxide modulation 4
The American Heart Association acknowledges that nebivolol reduces blood pressure as effectively as other standard antihypertensive medications, including ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers 4
A systematic review and meta-analysis found that nebivolol was superior to other beta-blockers and diuretics for systolic blood pressure management, and equally effective compared to angiotensin receptor blockers and calcium channel blockers 4

The European Society of Cardiology guidelines state that nebivolol has been shown to be effective across different patient populations, including Black patients, though the magnitude of effect as monotherapy may be somewhat less than in Caucasians 2
Nebivolol has demonstrated benefits in patients with heart failure, with the SENIORS trial showing nebivolol significantly decreased all-cause mortality or cardiovascular hospital admissions in elderly patients with heart failure 5
The European Society of Cardiology notes that nebivolol has a favorable effect on glycemic control compared to some other beta-blockers, making it a suitable option for patients with diabetes mellitus 4
The American Diabetes Association recommends careful monitoring of blood glucose levels during the initiation of nebivolol therapy in patients with diabetes mellitus, due to its potential effects on glycemic control 4

The recommended dose for hypertension is 5 mg daily, while for heart failure, treatment is initiated with a lower dose (usually 1.25 mg) and titrated according to tolerance 6
The FDA-approved dosing regimen for hypertension is as follows:

Nebivolol is contraindicated in patients with severe bradycardia, AV block of second or third degree, cardiogenic shock, decompensated heart failure, and sick sinus syndrome (unless a permanent pacemaker is in place) 5
Common adverse effects include hypotension (low blood pressure), bradycardia (slow heart rate), dizziness, and fatigue, with hypotension being a notable side effect 6
Other adverse effects, such as AV block (a conduction disorder of the heart) and confusion (especially in older patients), have also been associated with nebivolol 6

Nebivolol is metabolized by the cytochrome P-450 isoenzyme 2D6, and caution is advised when co-administering with drugs that affect this enzyme 4
Nebivolol may increase the effect of other blood pressure-lowering medications, and its use should be carefully monitored in patients receiving concomitant therapy 6